Last reviewed · How we verify

NCT05317260

Steatohepatitis in Chronic Hepatitis B

Completed Last updated 7 April 2022
What this trial tests

trial testing Antiviral Agents in Fatty Liver in 408 participants. Completed in 31 December 2021.

Timeline
1 January 2002
Primary endpoint
31 December 2020
31 December 2021

Quick facts

Lead sponsorMahidol University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment408
Start date1 January 2002
Primary completion31 December 2020
Estimated completion31 December 2021
Sites1 location across Thailand

Drugs / interventions tested

Conditions studied

Sponsor

Mahidol University

Who can join

18 and older, any sex, with Fatty Liver or Chronic Hepatitis b. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fatty liver disease is increasingly recognized in patients with chronic hepatitis B (CHB). Whether concurrent fatty liver disease affects the long-term outcomes of CHB is unclear. The investigators performed a longitudinal study to investigate the prognostic relevance of concurrent fatty liver disease for patients with CHB receiving antiviral therapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Prognostic Relevance of Metabolic Dysfunction-associated Steatohepatitis for Patients with Chronic Hepatitis B.
    Rugivarodom M, Pongpaibul A, Chainuvati S, Nimanong S, et al · · 2023 · cited 11× · PMID 36406326 · DOI 10.14218/jcth.2022.00055

Verify or expand the search:

Other trials of Antiviral Agents

Trials testing the same drug.

Other recruiting trials for Fatty Liver

Currently open trials in the same condition.

Other Mahidol University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05317260.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing